The Serum Institute has sought the Centre’s approval to export 32.4 lakh doses of the COVID-19 jab Covovax underneath the model identify Nuvaxovid to the US, which would be the first vaccine to be exported to the nation by any Indian producer, official sources mentioned on Thursday.
According to a communication despatched to the federal government by Prakash Kumar Singh, Director, Government and Regulatory Affairs on the SII, the cargo is more likely to be dispatched on July 3 if due approval are available time, an official supply advised PTI.
The sources mentioned will probably be the primary occasion of any Indian producer’s vaccine — Covid or non-Covid — to be exported to the US.
“It is a matter of pride for us and our country that in line with clarion call of our Prime Minister Narendra Modi ji’s ‘Making in India for the world’ and under leadership of our CEO, Dr Adar C. Poonawalla, our made in India world class Covovax vaccine will be the first life-saving vaccine of our country to be exported to United States of America. Also, our firm is committed to fulfill the dream of our PM to make India a pharmacy hub of the world,” Singh has mentioned in his communication, in line with an official supply.
On December 28, 2021, the Drugs Controller General of India (DCGI) had permitted Covovax for restricted use in emergency conditions in adults, and within the 12-17 yr age group on March 9 this yr.
On June 29, the drug regulator permitted it for restricted emergency use in kids aged 7 to 11 years.
Covovax is manufactured by way of know-how switch from Novavax and is permitted by the European Medicines Agency for conditional advertising and marketing authorization.
It was granted emergency use itemizing by the World Health Organization on December 2017, 2020. In August 2020, the US-based vaccine maker Novavax Inc had introduced a licence settlement with SII for the event and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in India and low and middle-income nations.
Source: www.financialexpress.com”